$DRIO
DarioHealth Corp. Stock $drio

$drio Overview Financials Valuation SEC Filings Company Website

2018 Q1 Form 10-K Financial Statement

#000114420418015415 Filed on March 19, 2018

Income Statement

Concept	2018 Q1	2016 Q4	2016
Revenue	$1.756M	$840.0K	$2.803M
YoY Change	74.38%	170.97%	240.58%
Cost Of Revenue	$1.204M	$1.220M	$3.364M
YoY Change	33.63%	114.04%	100.48%
Gross Profit	$552.0K	-$380.0K	-$830.0K
YoY Change	420.75%	46.15%	-2.92%
Gross Profit Margin	31.44%	-45.24%	-29.61%
Selling, General & Admin	$2.730M	$2.610M	$8.120M
YoY Change	-28.91%	153.4%	96.14%
% of Gross Profit	494.57%
Research & Development	$742.0K	$580.0K	$2.154M
YoY Change	57.87%	1.75%	-16.02%
% of Gross Profit	134.42%
Depreciation & Amortization	$53.00K	$120.0K	$387.0K
YoY Change	23.26%	33.33%	15.52%
% of Gross Profit	9.6%
Operating Expenses	$3.467M	$3.180M	$10.27M
YoY Change	-19.58%	98.75%	50.09%
Operating Profit	-$2.915M	-$3.560M	-$11.10M
YoY Change	-30.68%	91.4%	44.21%
Interest Expense	-$10.00K	-$1.430M	$230.0K
YoY Change	-99.17%	-815.0%	-60.34%
% of Operating Profit
Other Income/Expense, Net	-$4.000K	$20.00K	$214.0K
YoY Change	-99.67%	-300.0%	-61.51%
Pretax Income	-$2.920M	-$5.240M	-$3.972M
YoY Change	-46.03%	213.77%	407.28%
Income Tax
% Of Pretax Income
Net Earnings	-$2.919M	-$5.240M	-$10.89M
YoY Change	-46.07%	213.77%	52.44%
Net Earnings / Revenue	-166.23%	-623.81%	-388.41%
Basic Earnings Per Share
Diluted Earnings Per Share	-$3.893M	-$18.07M	-$41.88M
COMMON SHARES
Basic Shares Outstanding	16.45M shares	5.713M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q1	2016 Q4	2016
SHORT-TERM ASSETS
Cash & Short-Term Investments	$7.200M	$1.300M	$1.320M
YoY Change	132.26%	-53.57%	-52.0%
Cash & Equivalents	$7.041M	$1.093M	$1.090M
Short-Term Investments	$200.0K	$200.0K	$230.0K
Other Short-Term Assets		$64.00K	$500.0K
YoY Change		190.91%	-46.24%
Inventory	$900.0K	$888.0K	$890.0K
Prepaid Expenses
Receivables	$200.0K	$0.00	$230.0K
Other Receivables	$600.0K	$500.0K	$0.00
Total Short-Term Assets	$8.900M	$2.936M	$2.940M
YoY Change	74.51%	-31.51%	-31.47%
LONG-TERM ASSETS
Property, Plant & Equipment	$800.0K	$901.0K	$900.0K
YoY Change	-11.11%	20.29%	20.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$0.00	$0.00	$40.00K
YoY Change			0.0%
Total Long-Term Assets	$900.0K	$936.0K	$930.0K
YoY Change	0.0%	18.48%	17.72%
TOTAL ASSETS
Total Short-Term Assets	$8.900M	$2.936M	$2.940M
Total Long-Term Assets	$900.0K	$936.0K	$930.0K
Total Assets	$9.800M	$3.872M	$3.870M
YoY Change	63.33%	-23.73%	-23.82%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.100M	$1.800M	$1.810M
YoY Change	-26.67%	80.0%	84.69%
Accrued Expenses		$622.0K	$1.110M
YoY Change		43.32%	63.24%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.400M	$2.925M	$2.930M
YoY Change	-11.11%	73.08%	73.37%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Other Long-Term Liabilities	$0.00	$7.500M	$7.490M
YoY Change		188.46%	186.97%
Total Long-Term Liabilities	$0.00	$7.500M	$7.490M
YoY Change		50.0%	50.7%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.400M	$2.925M	$2.930M
Total Long-Term Liabilities	$0.00	$7.500M	$7.490M
Total Liabilities	$2.400M	$10.40M	$10.41M
YoY Change	-14.29%	55.22%	56.31%
SHAREHOLDERS EQUITY
Retained Earnings		-$54.96M
YoY Change		26.77%
Common Stock		$6.000K
YoY Change		20.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$7.371M	-$6.541M	-$6.540M
YoY Change
Total Liabilities & Shareholders Equity	$9.800M	$3.872M	$3.870M
YoY Change	63.74%	-23.73%	-23.82%

Cashflow Statement

Concept	2018 Q1	2016 Q4	2016
OPERATING ACTIVITIES
Net Income	-$2.919M	-$5.240M	-$10.89M
YoY Change	-46.07%	213.77%	52.44%
Depreciation, Depletion And Amortization	$53.00K	$120.0K	$387.0K
YoY Change	23.26%	33.33%	15.52%
Cash From Operating Activities	-$2.766M	-$1.860M	-$8.379M
YoY Change	-10.28%	-10.14%	33.42%
INVESTING ACTIVITIES
Capital Expenditures	$12.00K	-$400.0K	$808.0K
YoY Change		900.0%	634.55%
Acquisitions
YoY Change
Other Investing Activities	$70.00K	$10.00K	-$140.0K
YoY Change	-800.0%	-200.0%
Cash From Investing Activities	$55.00K	-$390.0K	-$947.0K
YoY Change	-711.11%	875.0%	760.91%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	6.034M	0.000	$7.748M
YoY Change	25.29%	-100.0%	1.81%
NET CHANGE
Cash From Operating Activities	-2.766M	-1.860M	-$8.379M
Cash From Investing Activities	55.00K	-390.0K	-$947.0K
Cash From Financing Activities	6.034M	0.000	$7.748M
Net Change In Cash	3.323M	-2.250M	-$1.578M
YoY Change	92.75%	-392.21%	-229.34%
FREE CASH FLOW
Cash From Operating Activities	-$2.766M	-$1.860M	-$8.379M
Capital Expenditures	$12.00K	-$400.0K	$808.0K
Free Cash Flow	-$2.778M	-$1.460M	-$9.187M
YoY Change	-9.89%	-28.08%	43.77%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2017	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2017	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2017	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2017Q2	dei	Entity Public Float EntityPublicFloat	14758157	USD
CY2017	dei	Trading Symbol TradingSymbol	DRIO
CY2018Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	16447914	shares
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3718000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1093000	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	504000	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	604000	USD
CY2016Q4	us-gaap	Short Term Investments ShortTermInvestments	225000	USD
CY2017Q4	us-gaap	Short Term Investments ShortTermInvestments	258000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	901000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	869000	USD
CY2016Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	35000	USD
CY2017Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	42000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	2936000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	6046000	USD
CY2017Q4	us-gaap	Inventory Net InventoryNet	1184000	USD
CY2016Q4	us-gaap	Inventory Net InventoryNet	888000	USD
CY2017Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	282000	USD
CY2016Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	226000	USD
CY2017Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1852000	USD
CY2016Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1812000	USD
CY2017Q4	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	1163000	USD
CY2016Q4	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	1113000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3015000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2925000	USD
CY2017Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1000	USD
CY2016Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	7488000	USD
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	7000	USD
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	6000	USD
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	74892000	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	48413000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-70958000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-54960000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	3941000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	-6541000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6957000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3872000	USD
CY2016	us-gaap	Revenues Revenues	2803000	USD
CY2017	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	USD
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	195000	USD
CY2017	drio	Payment For Executives And Directors Under Salary Program PaymentForExecutivesAndDirectorsUnderSalaryProgram	183000	USD
CY2017	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	334000	USD
CY2017	us-gaap	Revenues Revenues	5170000	USD
CY2017	us-gaap	Cost Of Goods Sold CostOfGoodsSold	3859000	USD
CY2016	us-gaap	Gross Profit GrossProfit	-830000	USD
CY2017	us-gaap	Gross Profit GrossProfit	1311000	USD
CY2016	us-gaap	Cost Of Goods Sold CostOfGoodsSold	3364000	USD
CY2016	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	4739000	USD
CY2016	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3378000	USD
CY2017	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4726000	USD
CY2016	us-gaap	Operating Expenses OperatingExpenses	10271000	USD
CY2017	us-gaap	Operating Expenses OperatingExpenses	15730000	USD
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	-11101000	USD
CY2016	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-260000	USD
CY2017	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1168000	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-10887000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-15743000	USD
CY2016	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11607000	USD
CY2017	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-15998000	USD
CY2016	us-gaap	Production Related Impairments Or Charges ProductionRelatedImpairmentsOrCharges	269000	USD
CY2017	us-gaap	Production Related Impairments Or Charges ProductionRelatedImpairmentsOrCharges	0	USD
CY2016	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	2.09
CY2017	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	1.64
CY2016	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	5202974	shares
CY2017	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	9628256	shares
CY2017	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	3824000	USD
CY2016	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	1038000	USD
CY2017	drio	Increase Decrease In Accounts Receivables And Prepaid Expense IncreaseDecreaseInAccountsReceivablesAndPrepaidExpense	99000	USD
CY2016	drio	Increase Decrease In Accounts Receivables And Prepaid Expense IncreaseDecreaseInAccountsReceivablesAndPrepaidExpense	-406000	USD
CY2017	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	39000	USD
CY2016	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	834000	USD
CY2016	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-31000	USD
CY2017	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	USD
CY2016	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	287000	USD
CY2017	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	295000	USD
CY2016	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	145000	USD
CY2017	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	17000	USD
CY2016	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	USD
CY2017	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-31000	USD
CY2016	drio	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	7538000	USD
CY2017	drio	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	13463000	USD
CY2016	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-1578000	USD
CY2017	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	2625000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2671000	USD
CY2016	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	2277000	USD
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	808000	USD
CY2016	drio	Payment For Executives And Directors Under Salary Program PaymentForExecutivesAndDirectorsUnderSalaryProgram	154000	USD
CY2016	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	378000	USD
CY2016	drio	Payments For Proceeds From Acquire Leases Held For Investment PaymentsForProceedsFromAcquireLeasesHeldForInvestment	-6000	USD
CY2017	drio	Payments For Proceeds From Acquire Leases Held For Investment PaymentsForProceedsFromAcquireLeasesHeldForInvestment	7000	USD
CY2016	drio	Proceeds From Stock Options And Warrants Exercised ProceedsFromStockOptionsAndWarrantsExercised	210000	USD
CY2017	us-gaap	Depreciation Depreciation	195000	USD
CY2016	us-gaap	Depreciation Depreciation	387000	USD
CY2017	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2016	us-gaap	Asset Impairment Charges AssetImpairmentCharges	269000	USD
CY2017	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	56000	USD
CY2016	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	226000	USD
CY2016	us-gaap	Inventory Write Down InventoryWriteDown	315000	USD
CY2017	us-gaap	Inventory Write Down InventoryWriteDown	190000	USD
CY2016	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3208430	shares
CY2017	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1434924	shares
CY2017	drio	Percentage Of Monthly Deposits Behalf Of Insurance Companies PercentageOfMonthlyDepositsBehalfOfInsuranceCompanies	0.0833	pure
CY2016Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	431000	USD
CY2016Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	457000	USD
CY2017Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	861000	USD
CY2017Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	323000	USD
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	735000	USD
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	491000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	428000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	622000	USD
CY2016	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	280000	USD
CY2017	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	301000	USD
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.25	pure
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.24	pure
CY2016Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	9944000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	445000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	10389000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	10389000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2017Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	10794000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	620000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	11414000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	11414000	USD
CY2017	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1025	USD
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-3972000	USD
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-6915000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-10599000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-5144000	USD
CY2016	drio	Bank Charges BankCharges	20000	USD
CY2017	drio	Bank Charges BankCharges	171000	USD
CY2016	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-26000	USD
CY2017	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	15000	USD
CY2017	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3824000	USD
CY2016	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1038000	USD
CY2017Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	1080000	USD
CY2017	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.07
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.86
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	980335	shares
CY2017	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	91855	shares
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	30274	shares
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	63380	shares
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	36.02
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	4.62
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	583334	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1378160	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1261465	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	696783	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	16.53
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.39
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	7.6
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	11.85
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	7000	USD
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	437000	USD
CY2017Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	357000	USD
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	437000	USD
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P4Y9M4D
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y7M20D
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y10M13D
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y9M
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.68
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2016	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	210000	USD
CY2016Q3	drio	Deemed Dividend Related To Exchange Agreement DeemedDividendRelatedToExchangeAgreement	265000	USD
CY2016Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	300000	shares
CY2016Q3	drio	Warrant Exercise Period WarrantExercisePeriod	P4Y6M
CY2016Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	4.5
CY2016	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	702000	USD
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	160000000	shares
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	160000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14074238	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14074238	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5713383	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5713383	shares
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016	drio	Deemed Dividend DeemedDividend	-710000	USD
CY2017	drio	Revaluation Of Short Term Bank Deposits RevaluationOfShortTermBankDeposits	17000	USD
CY2017Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	5100000	USD
CY2017Q1	drio	Stock Issued During Period Shares New Issues February2014 StockIssuedDuringPeriodSharesNewIssuesFebruary2014	1821437	shares
CY2017	drio	Deemed Dividend DeemedDividend	-255000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	295000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	220000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	200000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	200000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	1302000	USD
CY2017	drio	Stock Issued During Period Private Placement Value New Issues March2017 StockIssuedDuringPeriodPrivatePlacementValueNewIssuesMarch2017	1878000	USD
CY2017	drio	Issuance Of Common Stock In August2017 Private Placement Net Of Issuance Cost IssuanceOfCommonStockInAugust2017PrivatePlacementNetOfIssuanceCost	801000	USD
CY2017	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	0	USD
CY2016	drio	Revaluation Of Short Term Bank Deposits RevaluationOfShortTermBankDeposits		USD
CY2017	us-gaap	Dividends Common Stock Stock DividendsCommonStockStock	0	USD
CY2017	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	0	USD
CY2017	drio	Stock Issued During Period Public Offering Value New Issues April2017 StockIssuedDuringPeriodPublicOfferingValueNewIssuesApril2017	3855000	USD
CY2017	drio	Preferred Stock Issued During Period Private Placement Value New Issues August2017 PreferredStockIssuedDuringPeriodPrivatePlacementValueNewIssuesAugust2017	3711000	USD
CY2017Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	3655056	shares
CY2017Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	4.34
CY2017Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	451000	USD
CY2016Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	440000	USD
CY2017Q4	us-gaap	Other Assets Current OtherAssetsCurrent	153000	USD
CY2016Q4	us-gaap	Other Assets Current OtherAssetsCurrent	64000	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10619000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1346000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1187000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	477000	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	286000	USD
CY2017Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	40369	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-15743000	USD
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-10887000	USD
CY2017Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1871436	shares
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	-1580000	USD
CY2016	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1572000	USD
CY2016	drio	Stock Issued During Period Private Placement Value New Issues March2016 StockIssuedDuringPeriodPrivatePlacementValueNewIssuesMarch2016	828000	USD
CY2016	drio	Issuance Of Common Stock In January2016 To Service Provider IssuanceOfCommonStockInJanuary2016ToServiceProvider	37000	USD
CY2016	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	310000	USD
CY2016	drio	Stock Issued During Period Value Issued To Officer StockIssuedDuringPeriodValueIssuedToOfficer	86000	USD
CY2016	drio	Stock Issued During Period Value Stock Warrants Exercised StockIssuedDuringPeriodValueStockWarrantsExercised	210000	USD
CY2016	drio	Deemed Dividend Related To Change In Conversion Term Of Series Preferred Stock Value DeemedDividendRelatedToChangeInConversionTermOfSeriesPreferredStockValue	0	USD
CY2016	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	0	USD
CY2016	drio	Deemed Dividend Related To Exchange Agreement Adjustment DeemedDividendRelatedToExchangeAgreementAdjustment	0	USD
CY2016	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	605000	USD
CY2017	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1294000	USD
CY2017	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	707000	USD
CY2017	drio	Stock Issued During Period Private Placement Value New Issues January2017 StockIssuedDuringPeriodPrivatePlacementValueNewIssuesJanuary2017	2936000	USD
CY2017	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	1514000	USD
CY2017	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	874000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	387000	USD
CY2017	us-gaap	Stock Issued During Period Shares Share Based Compensation Gross StockIssuedDuringPeriodSharesShareBasedCompensationGross	110987	shares
CY2017Q4	drio	Service Fees Payable ServiceFeesPayable	298000	USD
CY2017Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1450000	shares
CY2017Q2	drio	Stock Issued Price Per Share StockIssuedPricePerShare	3.10
CY2017Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3855	USD
CY2017Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	36250	shares
CY2017Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	3.875
CY2017Q4	drio	Preferred Stock Issued During Period Private Placement Share New Issues August2017 PreferredStockIssuedDuringPeriodPrivatePlacementShareNewIssuesAugust2017	2307654	shares
CY2017	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -56.7pt; MARGIN: 0pt 0px 0pt 56.7pt; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"></div> <table style="MARGIN-BOTTOM: 0pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid; WIDTH: 100%; BORDER-BOTTOM: 0px solid; FONT: 10pt Times New Roman, Times, Serif; BORDER-LEFT: 0px solid; MARGIN-TOP: 0pt; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 56.7pt"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> <td style="WIDTH: 28.35pt"> <div style="CLEAR:both;CLEAR: both">a.</div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">Use of estimates:</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt; TEXT-INDENT: -56.7pt; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 85.05pt; font-size-adjust: none; font-stretch: normal" align="justify">The preparation of the consolidated financial statements and related disclosures in conformity with U.S. GAAP and the Company’s discussion and analysis of its financial condition and operating results require the Company’s management to make judgments, assumptions and estimates that affect the amounts reported in its consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on various other assumptions it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates, and such differences may be material.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: bold 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 85.05pt; TEXT-INDENT: 0in; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 85.05pt; font-size-adjust: none; font-stretch: normal" align="justify">Management believes the Company’s critical accounting policies and estimates are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017	us-gaap	Revenue Recognition Software RevenueRecognitionSoftware	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.35pt; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"></div> <table style="MARGIN-BOTTOM: 0pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid; WIDTH: 100%; BORDER-BOTTOM: 0px solid; FONT: 10pt Times New Roman, Times, Serif; BORDER-LEFT: 0px solid; MARGIN-TOP: 0pt; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top; FONT-WEIGHT: normal; FONT-STYLE: normal"> <td style="WIDTH: 56.7pt; FONT-WEIGHT: normal; FONT-STYLE: normal"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> <td style="WIDTH: 28.35pt; FONT-WEIGHT: normal; FONT-STYLE: normal"> <div style="CLEAR:both;CLEAR: both">j.</div> </td> <td style="FONT-WEIGHT: normal; FONT-STYLE: normal; TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">Revenue recognition:</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 85.5pt; TEXT-INDENT: 0in; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 85.05pt; TEXT-INDENT: 0in; font-size-adjust: none; font-stretch: normal" align="justify">Revenues from product sales are recognized in accordance with ASC 605-10 “Revenue Recognition”, when delivery has occurred, persuasive evidence of an agreement exists, the vendor’s fee is fixed or determinable, no further obligation exists and collectability is probable.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: bold 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 85.05pt; TEXT-INDENT: 0in; font-size-adjust: none; font-stretch: normal" align="justify">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 85.05pt; font-size-adjust: none; font-stretch: normal" align="justify">The Company derives revenues from the sale of its Dario Smart Meter and its related device-specific disposables test strip cartridges and lancets through independent distributors or directly to end users. The Dario software application is offered for a free download and the Company does not obtain a recurring hosting commitment towards the end users relating specifically to the application.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 85.05pt; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 85.05pt; font-size-adjust: none; font-stretch: normal" align="justify">The Company generally has a standard contract with its distributors. According to the agreements, all sales to distributors are final, no rights of return or price protection right is granted to such distributors and the Company is not a party of the agreements between distributors and their customers.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 85.05pt; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 85.05pt; font-size-adjust: none; font-stretch: normal" align="justify">Commencing July 1, 2016, product sales to distributors are recognized as revenues upon delivery, when the fee is fixed or determinable and collectability is probable<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017	drio	Proceeds From Stock Options And Warrants Exercised ProceedsFromStockOptionsAndWarrantsExercised	0	USD
CY2017Q4	us-gaap	Dividends Common Stock Stock DividendsCommonStockStock	255000	USD
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35	pure
CY2017	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	8655000	USD
CY2017	drio	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised		USD
CY2017	drio	Warrant Exercised WarrantExercised	8655000	USD
CY2016	drio	Warrant Exercised WarrantExercised	0	USD
CY2017	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"></div> <table style="MARGIN-BOTTOM: 0pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid; WIDTH: 100%; BORDER-BOTTOM: 0px solid; FONT: 10pt Times New Roman, Times, Serif; BORDER-LEFT: 0px solid; MARGIN-TOP: 0pt; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 56.7pt"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> <td style="WIDTH: 28.35pt"> <div style="CLEAR:both;CLEAR: both">l.</div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">Concentrations of credit risk:</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 85.05pt; font-size-adjust: none; font-stretch: normal" align="justify">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents, short-term bank deposits and trade receivables.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 85.05pt; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 85.05pt; font-size-adjust: none; font-stretch: normal" align="justify">All of the cash and cash equivalents and short-term bank deposits of the Company and its Subsidiary are invested in deposits and current accounts with major U.S. and Israeli banks. Such cash and cash equivalents and short-term bank deposits may be in excess of insured limits and are not insured in other jurisdictions. Generally, cash and cash equivalents and short-term bank deposits may be redeemed and therefore a minimal credit risk exists with respect to these deposits and investments.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: bold 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 85.05pt; TEXT-INDENT: 0in; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 85.05pt; TEXT-INDENT: 0in; font-size-adjust: none; font-stretch: normal" align="justify">The Company's trade receivables are derived mainly from sales to distributers and to end-users world-wide. The Company performs ongoing credit evaluations of its customers. An allowance for doubtful accounts is determined with respect to those specific amounts that the Company has determined to be doubtful of collection.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 85.05pt; TEXT-INDENT: 0in; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 85.05pt; TEXT-INDENT: 0in; font-size-adjust: none; font-stretch: normal" align="justify">The Company had no off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017Q4	us-gaap	Stock Issued During Period Shares Share Based Compensation Gross StockIssuedDuringPeriodSharesShareBasedCompensationGross	138459	shares
CY2017Q4	drio	Class Of Warrant Or Right Aggregate With Shares Consideration ClassOfWarrantOrRightAggregateWithSharesConsideration	1039676	shares
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8379000	USD
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-219000	USD
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-947000	USD
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	13463000	USD
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7748000	USD

Files In Submission

Name	View Source	Status
0001144204-18-015415-index-headers.html	Edgar Link	pending
0001144204-18-015415-index.html	Edgar Link	pending
0001144204-18-015415.txt	Edgar Link	pending
0001144204-18-015415-xbrl.zip	Edgar Link	pending
drio-20171231.xml	Edgar Link	completed
drio-20171231.xsd	Edgar Link	pending
drio-20171231_cal.xml	Edgar Link	unprocessable
drio-20171231_def.xml	Edgar Link	unprocessable
drio-20171231_lab.xml	Edgar Link	unprocessable
drio-20171231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tv487753_10k.htm	Edgar Link	pending
tv487753_ex10-36.htm	Edgar Link	pending
tv487753_ex10-37.htm	Edgar Link	pending
tv487753_ex23-1.htm	Edgar Link	pending
tv487753_ex31-1.htm	Edgar Link	pending
tv487753_ex31-2.htm	Edgar Link	pending
tv487753_ex32-1.htm	Edgar Link	pending
tv487753_img1.jpg	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DRIO
DarioHealth Corp. Stock $drio

2018 Q1 Form 10-K Financial Statement

#000114420418015415 Filed on March 19, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DRIO DarioHealth Corp. Stock $drio

2018 Q1 Form 10-K Financial Statement

#000114420418015415 Filed on March 19, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DRIO
DarioHealth Corp. Stock $drio